|Email Newsletters from Pharmaceutical Technology and Pharmaceutical Technology Europe|
News from Europe's pharmaceutical manufacturing industry coupled with upcoming events, and exclusive articles and interviews from industry experts.
Pharmacosomes: A Potential Alternative to Conventional Vesicular Systems
Definition and usage. Pharmacosomes are the colloidal dispersions of drugs covalently bound to lipids and may exist as ultrafine vesicular, micellar, or hexagonal aggregates, depending on the chemical structure of the drug–lipid complex (4). Because the system is formed by linking a drug (pharmakon) to a carrier (soma), they are called pharmacosomes (5). Singh et al. used the expression "vesicular constructs" in common for pharmacosomes, liposomes, niosomes, and biosomes and encapsulated the antibiotic amoxicillin in their aqueous domains, which were prepared using phosphatidylethanolamine with various molar ratios of phosphatidyl-choline and cholesterol. They stabilized the formulation using an acylated protein base and reportedly improved cytoprotection and treatment of Helicobacter pylori infections in male rats (6).
In many aspects, pharmacosomes provide advantages over the use of other vesicular systems such as transferosomes, liposomes, and niosomes. Any drug possessing a free carboxyl group or an active hydrogen atom (–OH, NH2) can be esterified (with or without a spacer group) to the hydroxyl group of a lipid molecule, thus generating an amphiphilic prodrug. An amphiphilic prodrug is converted to pharmacosomes upon dilution with water (7). The prodrug conjoins hydrophilic and lipophilic properties (thereby acquiring amphiphilic characteristics), reduce interfacial tension, and, at higher concentrations, exhibit mesomorphic behavior (4). Because of a decrease in interfacial tension, the contact area increases, therefore increasing bioavailability (8). Some formulation approaches and in vivo performances of pharmacosomes are presented in this article.
Preparation. Two methods have been used to prepare vesicles: the hand-shaking method and the ether-injection method. In the hand-shaking method, the dried film of the drug–lipid complex (with or without egg lecithin) is deposited in a round-bottom flask and upon hydration with aqueous medium, readily gives a vesicular suspension. In the ether-injection method, an organic solution of the drug–lipid complex is injected slowly into the hot aqueous medium, wherein the vesicles are readily formed. Like other vesicular systems, pharmacosomes are characterized for attributes such as size and size distribution, nuclear magnetic resonance (NMR) spectroscopy, entrapment efficiency, in vitro release rate, and stability studies (9, 10).
An alternative approach for producing pharmacosomes was recently reported in which a biodegradable micelle-forming drug conjunct was synthesized from the hydrophobic drug adriamycin and a polymer composed of polyoxyethylene glycol and polyaspartic acid. This approach has the benefit that although it may be possible to dilute out the micelle, the drug will probably not precipitate because of the water solubility of the monomeric drug conjunct (11). Muller-Goymann and Hamann produced fenoprofen pharmacosomes using a modified technique that involved diluting lyotropic liquid crystals of amphiphilic drugs (12).
Attempts have been made to attach drugs such as β-blockers to various glyceride-like groups, and the resulting amphiphilic molecules have been spontaneously dispersed. They were labeled pharmacosomes because of their tendencies to form unilamellar vesicles. It was suggested that these molecules should enhance lymph transport (13). Zhang et al. attempted to optimize the preparation of 3', 5'-dioctanoyl-5-fluoro-2'-deoxyuridine pharmacosomes. Their study found that the drug phosphatidylcholine ratio, pluronic F-68 concentration, and glycerol tristearate concentration have an influence on the mean particle size, entrapment ratio, and drug loading (14).
Zhang and Wang showed that the pharmacosomes can improve the ability of a drug to cross the blood–brain barrier and act as a promising drug-targeting system for the treatment of central nervous system disorders (15). In another study, didanosine pharmacosomes were prepared and the in vivo behavior in rats was investigated. The study revealed liver targeting and sustained-release effect in rats after i.v. administration. The study found that there was targeting in the lung and spleen and that drug elimination from the target tissues was slow (16).
The approach of pharmacosomal drug delivery possesses many advantages over conventional vesicular systems. Pharmacosomes have immense potential, and further advantages of the vesicular system can be exploited by extending this approach to additional drugs. The influence of spacer groups and linkage also should be observed more rigorously for further improvement in drug-fate and biological activity of the drug to achieve the therapeutic goal.
Sandeep Sangwan is a research scholar, and Harish Dureja* is a lecturer, both at the department of pharmaceutical sciences, M.D. University, Rohtak 124 001, India, tel. +91 94163
57995, fax +91 1262 274169, firstname.lastname@example.org
*To whom all correspondence should be addressed.
1. Y. Jin et al., "Self-Assembled Drug Delivery Systems-Properties and In Vitro –In Vivo Behaviour of Acyclovir Self-Assembled Nanoparticles (san)," Int. J. Pharm. 309 (1–2), 199–207 (2006).
2. P. Goyal et al., "Liposomal Drug Delivery Systems: Clinical Applications," Acta Pharm. 55, 1–25 (2005).
3. H.A. Lieberman, M.M. Rieger, and G.S. Banker, Pharmaceutical Dosage Forms: Disperse Systems (Informa Healthcare, London, England, 1998), p. 163.
4. S.S. Biju et al., "Vesicular Systems: An Overview," Ind. Jour. Pharm. Sci. 68 (2), 141–153 (2006).
5. M.O. Vaizoglu and P.P. Speiser, "Pharmacosomes—A Novel Drug Delivery System," Acta Pharm. Suec. 23, 163–172 (1986).
6. A. Singh and R. Jain, "Targeted Vesicular Constructs For Cytoprotection and Treatment of H. Pylori Infections," US Patent 6576,625 (2003).
7. I.P. Kaur and M. Kanwar, "Ocular Preparations: The Formulation Approach," Drug Dev. Ind. Pharm. 28 (5), 473–493 (2002).
8. F. Volkering et al., "Influence of Nonionic Surfactants on Bioavailability and Biodegradation of Polycyclic Aromatic Hydrocarbons," App. Environ. Micro. 61 (5), 1699–1705 (1995).
9. A. Steve, "Lipophilic Drug Derivatives For Use In Liposomes," US Patent 5534499 (1996).
10. I. Taskintuna et al., "Evaluation Of A Novel Lipid Prodrug for Intraocular Drug Delivery: Effect of Acyclovir Diphosphate Dimyristoylglycerol in a Rabbit Model With Herpes Simplex Virus-1 Retinitis," Retin. 17 (1), 57–64, (1997).
11. M. J. Lawrence, "Surfactant Systems: Their Use in Drug Delivery," Chem. Soc. Rev. 23, 417–424 (1994).
12. C.C. Muller-Goymann and H.J. Hamann, "Pharmacosomes : Multilamellar Vesicles Consisting Of Pure Drug," Eur. J. Pharm. Biopharm. 37, 113–117 (1991).
13. J.S. Valentino and N.C. William, Lymphatic Transport of Drugs (CRC Press, Boca Raton, FL, 1992), pp. 205.
14. Z.R. Zhang, J.X. Wang, and J. Lu, "Optimization of the Preparation of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine Pharmacosomes Using Central Composite Design," Yao Xue Xue Bao 36 (6), 456–461 (2001).
15. Z.R. Zhang and J.X. Wang, "Study on Brain Targeting 3',5'-dioctanoyl-5-fluoro-2'-Deoxyuridine Pharmacosomes," Yao Xue Xue Bao. 36 (10), 771–776 (2001).
16. A. Ping, Y. Jin, and C. Da-wei, "Preparation and In Vivo Behavior of Didanosine Pharmacosomes in Rats," Chin. J. Pharm. 3, 227–235 (2005).
17. M. Gulati et al., "Lipophilic Drug Derivatives In Liposomes," Int. J. Pharm. 165, 129–168 (1998).
18. N.K. Jain, Advances In Controlled and Novel Drug Delivery ( CBS Publishers, New Delhi, India, 2003), p. 276.
19. S. Mantelli, P. Speiser, and H. Hauser, "Phase Behaviour of a Diglyceride Prodrug: Spontaneous Formation of Unilamellar Vesicles," Chem. Phys. Lipid. 37 (4), 329–343 (1985).